"The
Report Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated
Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
Global Markets Directs,
Atypical
Hemolytic Uremic Syndrome (Nondiarrhea-
Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016,
provides an overview of the Atypical Hemolytic Uremic Syndrome
(Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline
landscape.
The report provides
comprehensive information on the therapeutics under development for
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic
Uremic Syndrome), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally,
the report provides an overview of key players involved in
therapeutic development for Atypical Hemolytic Uremic Syndrome
(Nondiarrhea- Associated Hemolytic Uremic Syndrome) and features
dormant and discontinued projects.
Global Markets Directs report
features investigational drugs from across globe covering over 20
therapy areas and nearly 3,000 indications. The report is built using
data and information sourced from Global Markets Directs proprietary
databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources. Drug profiles featured in the report undergoes
periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.
The report helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/794422
Scope
-
The report provides a snapshot of the global therapeutic landscape of
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic
Uremic Syndrome)
-
The report reviews pipeline therapeutics for Atypical Hemolytic
Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved Atypical Hemolytic Uremic
Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
therapeutics and enlists all their major and minor projects
-
The report assesses Atypical Hemolytic Uremic Syndrome (Nondiarrhea-
Associated Hemolytic Uremic Syndrome) therapeutics based on drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news related to pipeline therapeutics for
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic
Uremic Syndrome)
Reasons to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand important and diverse types of therapeutics
under development for Atypical Hemolytic Uremic Syndrome
(Nondiarrhea- Associated Hemolytic Uremic Syndrome)
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic
Uremic Syndrome) pipeline depth and focus of Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report
Coverage 7
Atypical Hemolytic Uremic
Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Overview
8
Therapeutics Development 9
Pipeline Products for Atypical
Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic
Syndrome) - Overview 9
Atypical Hemolytic Uremic
Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) -
Therapeutics under Development by Companies 10
Atypical Hemolytic Uremic
Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) -
Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Atypical Hemolytic Uremic
Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) -
Products under Development by Companies 14
Atypical Hemolytic Uremic
Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) -
Companies Involved in Therapeutics Development 15
Achillion Pharmaceuticals, Inc.
15
Akari Therapeutics, Plc 16
Alexion Pharmaceuticals, Inc.
17
Amgen Inc. 18
ChemoCentryx, Inc. 19
Epirus Biopharmaceuticals, Inc.
20
greenovation Biotech GmbH 21
Kedrion S.p.A. 22
Omeros Corporation 23
Ra Pharmaceuticals, Inc. 24
Atypical Hemolytic Uremic
Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) -
Therapeutics Assessment 25
Assessment by Monotherapy
Products 25
Assessment by Target 26
Assessment by Mechanism of
Action 28
Assessment by Route of
Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ACH-4471 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ALXN-1210 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CCX-168 - Drug Profile 38
Product Description 38
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment